We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions
Product News

Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions

Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions
Product News

Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.

In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower healthcare professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole.

The rapid, high-quality assays run on Beckman Coulter’s scalable AU clinical chemistry analysers and shorten turnaround time for patient test results to hours instead of days – leading to greater success managing and monitoring treatments for inpatients and outpatients.

Serious mental illness is a significant public health concern. Worldwide 45 million people are affected by bipolar disorder and 24 million people are living with schizophrenia. Patients with untreated schizophrenia or bipolar may experience increased intensity of symptoms which could be disabling, potentially resulting in additional medical care or could lead to suicide. These new assays assist healthcare professionals to evaluate patient treatment adherence and individual patient drug response.

Kathleen Orland, senior vice president & general manager, clinical chemistry and immunoassay, Beckman Coulter, says: “Beckman Coulter’s portfolio of therapeutic drug monitoring assays offers laboratories and diagnostic testing facilities ways to improve patient care by ensuring therapeutic ranges are monitored. Our relationship with Saladax expands access for laboratories and clinicians to antipsychotic drug testing for treatment of psychotic disorders, which is a growing healthcare need .”

Sal Salamone, CEO and founder, Saladax, says: “Our partnership with Beckman Coulter is a major step in making these important antipsychotic tests available to healthcare professionals. These tests provide timely quantitative insights so they can make reliable assessments that will improve the care of patients with serious mental illness.”

Assays are being introduced across Europe and the US, with plans to expand to Beckman Coulter customers globally. For more information about Beckman Coulter’s Antipsychotic Drug Testing addition to Therapeutic Drug Monitoring, visit www.beckmancoulter.com/antipsychotic.


Advertisement